GlassScriptPhysician profile
Melissa J Kistner
NPI 1679051106
$3,412.24
in general payments reported to CMS, 2019-2025
28 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038 · 2022: $604 · 2023: $532 · 2024: $489 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $892.22 | 2021-2025 | Dupixent |
| Genzyme Corporation | $403.30 | 2021-2025 | |
| Csl Behring | $339.55 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Biocryst US Sales Co., LLC | $302.54 | 2021-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $286.18 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $193.33 | 2022-2025 | Takhzyro |
| Pharming Healthcare, INC. | $168.93 | 2024-2025 | Ruconest |
| Jazz Pharmaceuticals INC. | $104.89 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $91.91 | 2022 | |
| Intersect Ent, INC. | $80.55 | 2022 | |
| Optinose US, INC. | $67.58 | 2022-2023 | |
| Alk-Abello, INC | $62.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.86 | 2021-2025 | |
| Kaleo, INC. | $39.07 | 2021-2022 | |
| Octapharma USA, INC. | $38.34 | 2024-2025 | Cutaquig |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $33.06 | 2025 | Inspire |
| Hikma Pharmaceuticals USA | $32.84 | 2023 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $31.30 | 2025 | Tezspire, Airsupra |
| Welch Allyn | $29.80 | 2021 | |
| Genentech USA, INC. | $29.05 | 2025 | Xolair |
| Lilly USA, LLC | $23.32 | 2025 | Zepbound |
| Ars Pharmaceuticals Operations, INC. | $22.65 | 2025 | Neffy |
| Pfizer INC. | $19.80 | 2024 | |
| Currax Pharmaceuticals LLC | $17.62 | 2021 | |
| Cycle Pharmaceuticals INC | $16.58 | 2025 | Sajazir |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 | |
| Ionis Pharmaceuticals, INC. | $16.20 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Kistner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.